• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Lumito

2.75 SEK

+7.65 %

Less than 1K followers

LUMITO

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+7.65 %
-1.96 %
-36.53 %
-60.79 %
-65.69 %
-96.68 %
-99.25 %
-99.28 %
-98.87 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
9.45M SEK
Turnover
20.03K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7.7.
2026

Extraordinary general meeting '26

20.8.
2026

Interim report Q2'26

29.10.
2026

Interim report Q3'26

Regulatory press release6/11/2026, 11:00 AM

Lumito strengthens Scientific Advisory Board with internationally leading experts in life science and drug development

Lumito
Regulatory press release5/27/2026, 7:00 AM

Lumito awarded Vinnova funding to strengthen regulatory and quality capabilities during commercialisation

Lumito
Regulatory press release5/25/2026, 12:15 PM

Subscription price for the exercise of warrants of series TO7 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/7/2026, 6:30 AM

Lumito AB publishes Interim Report Q1 2026

Lumito
Regulatory press release5/5/2026, 9:00 AM

Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

Lumito
Regulatory press release5/4/2026, 8:00 AM

Simpler biomarker workflows without compromising sensitivity: new white paper shows how researchers gain reproducible, quantitative IHC results in fewer steps

Lumito
Regulatory press release4/9/2026, 6:30 AM

Lumito’s CRO strategy generates revenue through collaboration with Truly Labs AB

Lumito
Regulatory press release4/2/2026, 6:30 AM

Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis

Lumito
Regulatory press release3/18/2026, 8:00 AM

Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito’s UCNP imaging and Tethis’ SmartBioSurface® slides

Lumito
Regulatory press release3/12/2026, 8:15 AM

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Lumito
Regulatory press release3/10/2026, 2:15 PM

Lumito publishes equity research report on Lumito

Lumito
Regulatory press release3/10/2026, 10:45 AM

Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day

Lumito
Regulatory press release2/20/2026, 7:30 AM

Lumito AB publishes year-end report 2025

Lumito
Regulatory press release2/18/2026, 8:20 AM

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Lumito
Regulatory press release2/17/2026, 2:00 PM

Invitation to webinar in connection with Lumito AB’s year-end report for 2025

Lumito
Regulatory press release2/3/2026, 8:40 AM

Lumito initiates pilot project with leading professor in urological cancer research at Lund University

Lumito
Regulatory press release1/30/2026, 2:45 PM

Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series TO7

Lumito
Regulatory press release1/29/2026, 8:15 AM

Lumito receives patent approval in India

Lumito
Regulatory press release1/28/2026, 7:30 AM

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Lumito
Regulatory press release1/23/2026, 1:50 PM

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Lumito